Salute e Benessere
Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
Elevated ApoC3 drives triglyceride-rich lipoprotein accumulation, increasing risks of acute pancreatitis and cardiovascular disease, particularly in diabetes. Current therapies often fail to achieve sustained control in severe cases. RN0361's profound, six-month efficacy from a single dose may address this unmet need and marks a significant advance in lipid management.
"These data confirm RN0361's long-acting potency and favorable safety profile, supporting its advancement in Phase 2 studies in patients with hypertriglyceridemia," said . "By profoundly lowering ApoC3, TG and atherogenic lipids for at least six months after a single dose, RN0361 is an important potential therapeutic for the critical unmet need in severe HTG and CVD risk reduction."
is a world-leading RNAi therapeutics company dedicated to addressing cardiometabolic, obesity and degenerative diseases with next generation RNA technology platform. Since its inception in 2021, the Company has progressed four programs into the clinic leveraging its proprietary platform in delivery, multi-valency and oligo chemistry. The Company has raised around $200M from global blue-chip healthcare investors and strategic partners.
View original content:https://www.prnewswire.co.uk/news-releases/rona-therapeutics-presents-phase-1-data-for-rn0361-a-long-acting-apoc3-targeting-sirna-at-the-american-heart-association-2025-scientific-sessions-302609508.html